Date: _Mar 29 th , 2022
Your Name: _Mingyao Zhou
Manuscript Title: Clostridium butyricum inhibits the progression of colorectal cancer and alleviates intestinal
inflammation via the myeloid differentiation factor 88 (MyD88)-nuclear factor-kappa B (NF- K B) signaling pathway
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China (#51972343, 51937011)	Funding
	medical writing, article processing charges, etc.) No time limit for this item.	Research Projects of Cancer Hospital Chinese Academy of Medical Sciences (#LC2020A24)	Funding
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	

3	Royalties or licenses	XNone
4	Consulting fees	XNone
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This study was supported by the National Natural Science Foundation of China (#51972343, 51937011) and Research Projects of Cancer Hospital Chinese Academy of Medical Sciences (#LC2020A24). And the author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: _Mar 29 th , 2022
Your Name: _Wei Yuan
Manuscript Title: Clostridium butyricum inhibits the progression of colorectal cancer and alleviates intestinal
inflammation via the myeloid differentiation factor 88 (MyD88)-nuclear factor-kappa B (NF- K B) signaling pathway
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China (#51972343, 51937011)	Funding
	medical writing, article	Research Projects of	Funding
	processing charges, etc.)	Cancer Hospital Chinese	
	No time limit for this item.	Academy of Medical	
		Sciences (#LC2020A24)	
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		

3	Royalties or licenses	XNone
4	Consulting fees	XNone
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This study was supported by the National Natural Science Foundation of China (#51972343, 51937011) and Research Projects of Cancer Hospital Chinese Academy of Medical Sciences (#LC2020A24). And the author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: _Mar 29 th , 2022
Your Name: _Bing Yang
Manuscript Title: Clostridium butyricum inhibits the progression of colorectal cancer and alleviates intestinal
inflammation via the myeloid differentiation factor 88 (MyD88)-nuclear factor-kappa B (NF- $ exttt{ iny E}$ B) signaling pathway
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China (#51972343, 51937011)	Funding
	medical writing, article	Research Projects of	Funding
	processing charges, etc.)	Cancer Hospital Chinese	
	No time limit for this item.	Academy of Medical	
		Sciences (#LC2020A24)	
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		

3	Royalties or licenses	XNone
4	Consulting fees	XNone
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This study was supported by the National Natural Science Foundation of China (#51972343, 51937011) and Research Projects of Cancer Hospital Chinese Academy of Medical Sciences (#LC2020A24). And the author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: _Mar 29th, 2022	
Your Name: _Wei Pei_	
Manuscript Title: Clost	ridium butyricum inhibits the progression of colorectal cancer and alleviates intestinal
inflammation via the n	nyeloid differentiation factor 88 (MyD88)-nuclear factor-kappa B (NF- ${ t k}$ B) signaling pathway
Manuscript number (if	known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China (#51972343, 51937011)	Funding
	medical writing, article	Research Projects of	Funding
	processing charges, etc.)	Cancer Hospital Chinese	
	No time limit for this item.	Academy of Medical	
		Sciences (#LC2020A24)	
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		

3	Royalties or licenses	XNone
4	Consulting fees	XNone
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This study was supported by the National Natural Science Foundation of China (#51972343, 51937011) and Research Projects of Cancer Hospital Chinese Academy of Medical Sciences (#LC2020A24). And the author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: _Mar 29th, 2022	
Your Name: _Jie Ma	
Manuscript Title: Clostric	dium butyricum inhibits the progression of colorectal cancer and alleviates intestinal
inflammation via the my	eloid differentiation factor 88 (MyD88)-nuclear factor-kappa B (NF- 🗷 B) signaling pathway
Manuscript number (if k	nown):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China (#51972343, 51937011)	Funding
	medical writing, article	Research Projects of	Funding
	processing charges, etc.)	Cancer Hospital Chinese	
	No time limit for this item.	Academy of Medical	
		Sciences (#LC2020A24)	
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		

3	Royalties or licenses	XNone
4	Consulting fees	XNone
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None
11	Stock or stock options	X_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None
13	Other financial or non- financial interests	X_None

This study was supported by the National Natural Science Foundation of China (#51972343, 51937011) and Research Projects of Cancer Hospital Chinese Academy of Medical Sciences (#LC2020A24). And the author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: _Mar 29 th , 2022
Your Name: _Qiang Feng
Manuscript Title: Clostridium butyricum inhibits the progression of colorectal cancer and alleviates intestinal
inflammation via the myeloid differentiation factor 88 (MyD88)-nuclear factor-kappa B (NF- K B) signaling pathway
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China (#51972343, 51937011)	Funding
	medical writing, article	Research Projects of	Funding
	processing charges, etc.)	Cancer Hospital Chinese	
	No time limit for this item.	Academy of Medical	
		Sciences (#LC2020A24)	
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		

3	Royalties or licenses	XNone
4	Consulting fees	XNone
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None
11	Stock or stock options	X_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None
13	Other financial or non- financial interests	X_None

This study was supported by the National Natural Science Foundation of China (#51972343, 51937011) and Research Projects of Cancer Hospital Chinese Academy of Medical Sciences (#LC2020A24). And the author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement: